Well look at how this tech is used in the LifeWave X39 patch and its effects on the body
Following GLP1 treatment, participants reported having lost a median of 4.1 kg m 2 units of BMI (or 11.3 kg of weight), equivalent to a median of 11.7% of pre-treatment weight
As with all investigational medicines, the safety profiles of cagrilintide and retatrutide are still being characterised through ongoing clinical trials
It has potential therapeutic benefits, including gastrointestinal protection, wound and tissue healing, muscle recovery, anti-aging effects, and even possible cardiovascular and neurological benefits
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of IBD
No Reported Event Equals Safe Very small studies may be incapable of identifying uncommon, delayed or population-specific risks